

SUPPLEMENTAL TABLE 2 (Part 2 of 2)
FDA-APPROVED THERAPEUTICS FOR THE TREATMENT OF CANCER

DNA Repair Inhibitors			Increasing Precision	Cell-signaling Inhibitors		
Approved Indication	Generic Name	Trade Name		Approved Indication	Generic Name	Trade Name
certain types of ovarian, fallopian tube, and primary peritoneal cancers	niraparib	Zejula		certain type of breast cancer	abemaciclib	Verzenio
certain forms of breast, ovarian, pancreatic, and prostate cancers	olaparib*	Lynparza		certain types of leukemia and lymphoma*	acalabrutinib	Calquence
certain types of ovarian and prostate cancer	rucaparib*	Rubraca		HER2+ breast cancer	ado-trastuzumab emtansine	Kadcyla
certain type of breast cancer	talazoparib*	Talzenna		certain type of lung cancer	afatinib	Gilotrif
Immune Checkpoint Inhibitors				certain form of lung cancer	alectinib	Alecensa
Approved Indication	Generic Name	Trade Name		certain type of breast cancer	alpelisib*	Piqray
certain types of bladder, breast, and lung cancers	atezolizumab	Tecentriq		certain type of gastrointestinal stromal tumor	avapritinib	Ayvakit
certain types of bladder, kidney, and skin cancers	avelumab	Bavencio		certain type of leukemia	bosutinib	Bosulif
certain type of skin cancer	cemiplimab-rwlc	Libtayo		certain type of melanoma	binimetinib and encorafenib	Braftovi and Mektovi
certain types of bladder cancer and lung cancer	durvalumab	Imfinzi		certain type of lung cancer	brigatinib	Alunbrig
multiple cancers	ipilimumab	Yervoy		certain type of lung cancer	capmatinib	Tabrecta
multiple cancers	nivolumab	Opdivo		certain type of metastatic ALK-positive lung cancer	ceritinib	Zykadia
multiple cancers	pembrolizumab	Keytruda		colon cancer*; head and neck cancer	cetuximab	Erbitux
Bone-remodeling Inhibitors				certain type of colorectal cancer*	cetuximab and encorafenib*	Erbitux and Braftovi
Approved Indication	Generic Name	Trade Name		certain form of melanoma*	cobimetinib	Cotellic and Zelboraf
potentially lethal complication of advanced cancers*	denosumab	Xgeva		certain type of non-Hodgkin lymphoma	copanlisib	Aliqopa
Angiogenesis Inhibitors				specific lung cancers*	crizotinib	Xalkori
Approved Indication	Generic Name	Trade Name		multiple cancers	dabrafenib	Tafinlar
				certain type of lung cancer	dacomitinib*	Vizimpro
				some leukemias	dasatinib	Sprycel
				certain types of leukemia and non-Hodgkin lymphoma	duvelisib	Copiktra
				certain type of bladder cancer	enfortumab vedotin-ejfv	Padcev
				NTRK-positive solid tumors and certain lung cancers	entrectinib	Rozlytrek
				certain type of bladder cancer	erdafatinib*	Balversa
				certain type of breast cancer	fam-trastuzumab deruxtecan-nxki	Enhertu
				certain type of myeloproliferative neoplasm	fedratinib	Inrebic
				some lung cancers*; pancreatic cancer	erlotinib	Tarceva
				some pancreatic cancers; kidney cancer; noncancerous kidney tumors; HER2+ breast cancers; neuroendocrine tumors	everolimus	Afinitor
				lung cancer	gefitinib	Iressa
Oncolytic Virus			Increasing Precision	Cell-signaling Inhibitors		
Approved Indication	Generic Name	Trade Name		Approved Indication	Generic Name	Trade Name
melanoma	talimogene laherparepvec	Imlygic		certain type of leukemia	gilteritinib*	Xospata
Therapeutic Vaccine				certain type of leukemia	glasdegib	Daurismo
Approved Indication	Generic Name	Trade Name		certain form of lymphoma and non-Hodgkin lymphoma	ibrutinib	Imbruvica
prostate cancer	sipuleucel-T	Provenge		certain types of leukemia and lymphoma	idelalisib	Zydelig
CAR T-cell Therapy				some leukemias; stomach cancer; certain type of skin cancer	imatinib	Gleevec; Glivec
Approved Indication	Generic Name	Trade Name		HER2+ breast cancers	lapatinib	Tykerb
certain type of non-Hodgkin lymphoma	axicabtagene ciloleucel	Yescarta		NTRK-positive solid tumors	larotrectinib	Vitrakvi
certain types of leukemia and non-Hodgkin lymphoma	tisagenlecleucel	Kymriah		certain type of lung cancer	lorlatinib*	Lobrena
certain type of non-Hodgkin lymphoma	autoleucel brexucabtagene	Tecartus		certain types of leukemia	midostaurin*	Rydapt
				certain form of lung cancer	necitumumab	Portrazza
				certain type of breast cancer	neratinib	Nerlynx
				some leukemias	nilotinib	Tasigna
				soft tissue sarcoma	olaratumab	Lartruvo
				certain form of lung cancer*	osimertinib	Tagrisso
				certain subtype of breast cancer	palbociclib	Ibrance
				colon cancer	panitumumab	Vectibix
				certain type of bile duct cancer	pemigatinib*	Pemazyre
				HER2+ breast cancer	pertuzumab	Perjeta
				tenosynovial giant cell tumor	pexidartinib	Turalio
				certain types of leukemia	ponatinib	Iclusig
				certain type of breast cancer	ribociclib	Kisqali
				gastrointestinal stromal tumor	ripretinib	Qinlock
				myelofibrosis	ruxolitinib	Jakafi
				certain type of breast cancer	sacituzumab govitecan-hziy	Trodelyv
				certain types of lung and thyroid cancer	selpercatinib	Retemvo
				neurofibromatosis type 1	selumetinib	Koselugo
				most common type of skin cancer	sonidegib	Odomzo
				multiple cancers	trametinib	Mekinist
				HER2+ breast cancer	trastuzumab	Herceptin
				kidney cancer	temsirolimus	ToriceI; Torisel
				certain type of breast cancer	tucatinib	Tukysa
				thyroid cancer	vandetanib	Caprelsa
				certain type of blood cancer and melanoma*	vemurafenib	Zelboraf
				most common type of skin cancer	vismodegib	Erivedge
				certain type of non-Hodgkin lymphoma	zanubrutinib	Brukinsa

* includes companion diagnostic
Some drugs are available in multiple formulations; these have only been listed once.
Where multiple trade names are used, only the most common have been listed.
American Association for Cancer Research (AACR) Cancer Progress Report 2020